 This is an open-label study assessing antibody formation anti-RPE and anti-retinal in 5 groups. Group 1 n40 will include neovascular AMD patients treated with ranibizumab. Patients will be included and receive 4 ranibizumab 0.5mg intravitreally at 4-6 week intervals and then twice more as needed PRN at 4-6 week intervals. After the 4th ranibizumab injection, if a Group 1 patient has not responded persistent fluid on OCT, they will be moved into Group 3 anti-VEGF acute non-responders or Group 5 anti-VEGF chronic non-responders. This will reduce the eventual number of subjects enrolled in Group 1 to approximately 36, as we anticipate approximately 4 subjects to have to move to either Group 3 or Group 5 as a non-responder. Group 2 n40 will be an age-sex-race matched normal subjects from the population that does not have AMD. Group 3 n8 and Group 5 n7 for a combined total of 15 subjects, approximately 4 of whom transferred from Group 1 include patients treated with 4 or more injections of anti-VEGF treatment at 4-8 week intervals without an initial response Initial non-response is defined as 100 microns of improved decreased retinal thickening by OCT. Group 3 patients, the acute non-responders, will be included after the 4th injection and followed for 2 more visits at 4-8 week intervals during which time they can receive as needed anti-VEGF treatments at the investigators discretion for any fluid on OCT. Group 4 n40 will be age-sex-race matched patients with Dry AMD as controls for immune response before there is a neovascular response. Group 5 patients, the chronic non-responders, will be included after the 4th injection and followed for one 1 visit at Month 4 during which time they can receive an as needed anti-VEGF treatment at the investigators discretion for any fluid on OCT. 